Vitamin B 12 Deficiency

Slide 1 · Vitamin B₁₂ Deficiency

Subacute combined degeneration of the spinal cord

Neuropathology · Clinicopathologic correlations

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define subacute combined degeneration (SCD) as a B₁₂-related tract disorder.

Relate bilateral sensory and motor deficits to degeneration of spinal pathways.

Explain myelin vacuolation, late axonal loss, and the effect of treatment timing.

Connect absorption, biochemical roles, and systemic features to neurologic disease.

Slide 3 · Neurologic consequences distinguish B₁₂ deficiency

Vitamin deficiency can injure neural tissue as well as hematopoietic tissue.

Neurologic manifestations need not parallel the severity of megaloblastic anemia.

Prompt recognition is important because established motor disability may not recover.

Slide 4 · Why B-vitamin deficiencies affect the CNS

Neural tissue has substantial metabolic demands.

B vitamins participate in reactions essential for cellular metabolism.

B₁ and B₁₂ deficiency as major neurologic vitamin-deficiency syndromes.

Different principal syndromes

B₁ deficiency: Wernicke–Korsakoff spectrum

B₁₂ deficiency: Subacute combined degeneration

Slide 5 · Subacute combined degeneration: Definition

A neurologic disorder caused by vitamin B₁₂ deficiency.

Characterized by degeneration of both ascending and descending spinal tracts.

White-matter myelin injury is an early pathologic feature; Axonal degeneration may follow.

Slide 6 · Spinal cord tract distribution

Involvement of dorsal and lateral spinal tracts.

The combined pattern accounts for simultaneous sensory ataxia and spastic paraparesis.

The drawing identifies regions, not precise histologic lesion borders.

POSTERIOR

ANTERIOR

Dorsal tracts

Lateral tracts

Schematic regions · not a histologic section

Slide 7 · Dorsal tract injury and sensory ataxia

Ascending tracts convey sensory information from lower body pathways.

Dorsal-tract involvement corresponds to the sensory ataxia described in the text.

Sensory abnormalities often appear before severe motor impairment.

POSTERIOR

ANTERIOR

Dorsal tracts

Schematic regions · not a histologic section

Slide 8 · Lateral tract injury and spastic paraparesis

Descending motor tracts in lateral cord white matter may degenerate.

The clinical correlate is progressive spastic weakness of the lower extremities.

Severe progression can culminate in paraplegia.

POSTERIOR

ANTERIOR

Lateral tracts

Schematic regions · not a histologic section

Slide 9 · Typical neurologic presentation

Symptoms can evolve over several weeks.

Early symptoms often comprise symmetric numbness and tingling in both legs.

Mild gait ataxia may accompany the sensory complaints.

Spastic weakness generally characterizes more advanced disease.

Slide 10 · How symptoms typically evolve

A progressive, rather than abrupt, constellation of deficits.

Symmetric paresthesias

Lower-limb ataxia

Spastic weakness

Possible paraplegia

Later stages can carry substantially poorer neurologic recovery.

Slide 11 · Bilateral numbness and tingling

Paresthesias are an early neurologic complaint.

The described distribution is symmetric in both lower extremities.

Initial symptoms may be relatively mild despite evolving tract pathology.

Clinical localization cues

Two-sided sensory symptoms

Lower extremity predominance

Gradually progressive syndrome

Slide 12 · Sensory ataxia

Lower-limb incoordination may develop early in the syndrome.

Dorsal spinal tract degeneration provides a clinicopathologic explanation.

Ataxia occurring with paresthesias should prompt attention to cord pathology.

Mechanistic interpretation

Ascending tract dysfunction

Impaired coordinated sensory input

Unsteady lower-limb movement

Slide 13 · Progression to spastic weakness

Descending tract involvement adds a motor component.

The lower limbs may develop spastic weakness or paraparesis.

A combined sensory–motor phenotype reflects injury to more than one tract system.

Combined syndrome

Sensory ataxia + paresthesias

Spastic lower-limb weakness

Long-tract disease of the cord

Slide 14 · Paraplegia is a late adverse manifestation

Paraplegia may occur with advanced disease but is usually a later finding.

Its appearance indicates severe functional compromise.

Once paraplegia develops, recovery after replacement therapy is poor.

Slide 15 · Neurologic progression is clinically time-sensitive

Early

Progressive

Late

Symmetric sensory symptoms and slight ataxia; An opportunity for recognition.

Spastic weakness joins sensory deficits as descending tracts are affected.

Paraplegia may emerge; Textbook prognosis for recovery is poor.

Slide 16 · Initial localization favors the mid-thoracic cord

In early SCD, microscopic injury is preferentially centered at mid-thoracic levels.

The initial lesion is not described as a focal compressive mass.

Anatomical spread can extend the distribution beyond this segment.

Longitudinal distribution

Initially mid-thoracic region

Extension proximally

Extension distally

Slide 17 · Longitudinal extension of the lesion

The process may spread along the spinal axis after an initially favored level.

Mid-thoracic predilection

Proximal extension

Distal extension

Arrows represent possible spread, not a fixed sequence in every patient.

Slide 18 · SCD begins as a disorder of myelin integrity

The lesions reflect defective formation or maintenance of myelin.

The exact metabolic steps linking B₁₂ deficiency to myelin injury remain uncertain.

Pathology includes a myelin abnormality before extensive axonal destruction.

Slide 19 · Microscopic sequence: Myelin to axon

The histologic sequence explains why intervention before advanced injury matters.

Myelin-layer swelling

Vacuolar change

Later axon degeneration

This is an original schematic of the sequence reported by Robbins.

Slide 20 · Vacuolation is an early microscopic finding

Affected myelin layers become swollen.

Swelling creates vacuoles within the involved white-matter tracts.

Vacuolar change is a tissue-level correlate of altered myelin integrity.

Native schematic of myelin change

Intact compact myelin

Swollen layers

Vacuoles between layers

Slide 21 · Early versus later pathologic injury

Feature

Earlier injury

More advanced injury

Dominant lesion

Myelin-layer swelling

Associated axonal degeneration

Microscopic appearance

Vacuolar change

Myelin loss with axonal injury

Clinical significance

Potential for earlier improvement

Greater risk of lasting neurologic deficit

Slide 22 · Myelin and axons are affected in sequence

Myelin swelling and vacuolation directly.

Axon degeneration is a later component of the process.

The distinction helps explain incomplete reversibility in advanced disease.

Two structural targets

Myelin: Early prominent injury

Axon: Degeneration with time

Slide 23 · Morphology tracks the clinical combination

Dorsal white-matter injury correlates with sensory ataxia.

Lateral white-matter injury correlates with spastic paraparesis.

The distribution is combined, rather than a lesion restricted to one pathway.

POSTERIOR

ANTERIOR

Dorsal tracts

Lateral tracts

Schematic regions · not a histologic section

Slide 24 · Peripheral neurologic involvement can coexist

Peripheral nerves can show degenerative changes in vitamin B₁₂ deficiency.

Mixed axonal degeneration and demyelination in B₁₂-related neuropathy.

Peripheral nervous system injury may add to the long-tract syndrome.

Sites of involvement

Spinal cord long tracts

Peripheral nerves

Occasionally posterior-root ganglia

Slide 25 · Posterior-root ganglia are less frequently involved

Occasional degenerative changes in posterior-root ganglia.

This is not presented as the dominant lesion of the neurologic syndrome.

The characteristic lesion remains combined dorsal and lateral cord tract degeneration.

Slide 26 · Central and peripheral manifestations

Compartment

Main structural change

Clinical importance

Spinal cord

Dorsal and lateral tract demyelination ± axon loss

Sensory ataxia; Spastic paraparesis

Peripheral nerve

Axonal degeneration plus demyelination

Additional peripheral neurologic deficits

Posterior-root ganglion

Less frequent degenerative changes

Variable involvement; Not the defining lesion

Slide 27 · Neurologic disease may precede overt anemia

CNS lesions can be present without striking hematologic abnormalities.

A seemingly modest blood picture does not exclude serious neurologic consequences.

This dissociation is important in clinical recognition of the deficiency.

Slide 28 · Early treatment changes the outlook

Prompt B₁₂ replacement is associated with clinical neurologic improvement.

Therapy may halt progression or reverse some peripheral neurologic deficits.

Outcome depends partly on the extent of established neurologic damage.

Slide 29 · Why timing of replacement matters

Clinical state

Source-supported expectation

Early paresthesias / ataxia

Prompt replacement can produce improvement

Progressive lower-limb weakness

Progression may be halted; Recovery varies

Established paraplegia

Neurologic recovery is poor

Slide 30 · Vitamin B₁₂ is cobalamin

Cobalamin is an organometallic vitamin required for specific human enzymatic reactions.

Animal-derived foods—including meat, fish, milk and eggs—are major dietary sources.

B₁₂ deficiency can affect neurologic pathways and proliferating marrow cells.

Slide 31 · Intake, requirement and storage

Component

Robbins description

Daily requirement

Approximately 2–3 μg in the source text

Dietary supply

Adequate animal-product intake generally exceeds this amount

Body stores

Hepatic reserves can cover several years

Low intake

Strictly plant-based diets without reliable B₁₂ supply can be inadequate

Slide 32 · Normal cobalamin uptake crosses multiple organs

Failure at several distinct sites can produce clinically important deficiency.

Stomach release

Duodenal transfer

Ileal receptor uptake

Plasma delivery

The sequence is a simplified native diagram of Robbins Fig. 14.17.

Slide 33 · Stomach: B₁₂ must be released from food

Food-bound cobalamin is liberated by gastric digestion, including pepsin activity.

It initially associates with salivary haptocorrin.

Loss of gastric acid/pepsin secretion can compromise this initial release.

Stomach phase

Dietary protein–bound B₁₂

Gastric liberation

Binding to haptocorrin

Slide 34 · Duodenum: Pancreatic proteases transfer the carrier

Pancreatic proteases free cobalamin from haptocorrin.

Released B₁₂ is then available to bind intrinsic factor.

Exocrine pancreatic insufficiency may interrupt this step.

Duodenal phase

Haptocorrin–B₁₂ complex

Pancreatic proteolysis

B₁₂ binds intrinsic factor

Slide 35 · Intrinsic factor is indispensable for efficient absorption

Intrinsic factor is secreted by parietal cells in the fundic gastric mucosa.

The intrinsic factor–B₁₂ complex moves through the small intestine to the ileum.

Loss of intrinsic factor is central to pernicious anemia.

Cause–effect

Parietal cell loss

Intrinsic factor deficiency

Reduced B₁₂ uptake

Slide 36 · Terminal ileum: Receptor-mediated uptake

The intrinsic factor–B₁₂ complex binds an ileal epithelial receptor called cubilin.

The complex is internalized by endocytosis.

Ileal resection or ileal disease can prevent adequate absorption.

Ileal uptake

IF–B₁₂ complex reaches ileum

Cubilin-mediated binding

Enterocyte endocytosis

Slide 37 · Transcobalamin II delivers absorbed B₁₂

In ileal cells, B₁₂ associates with transcobalamin II.

The vitamin enters the plasma and is distributed to liver and other tissues.

Bone marrow and gastrointestinal epithelium are prominent recipient tissues.

Delivery

Ileal enterocyte

Transcobalamin II

Liver · marrow · other cells

Slide 38 · Absorption defects mapped to their sites

Site / step

Example of interference

Stomach release

Achlorhydria; Loss of pepsin

Intrinsic factor

Autoimmune gastritis; Gastrectomy

Duodenal transfer

Exocrine pancreatic insufficiency

Ileal uptake

Ileal resection; Diffuse ileal disease

Luminal availability

Tapeworm competition; Bacterial overgrowth

Slide 39 · Oral absorption has a passive component

A small amount of cobalamin is absorbed by passive diffusion.

This uptake is inefficient compared with intrinsic factor–dependent absorption.

It explains why sufficiently high-dose oral replacement can be effective in some settings, including pernicious anemia.

Slide 40 · Mechanistic categories of B₁₂ deficiency

Category

Examples

Decreased intake

Inadequate diet; Strict diets lacking dependable B₁₂ sources

Failure of intrinsic factor

Pernicious anemia; Gastrectomy

Intestinal malabsorption

Diffuse intestinal disorders; Ileitis; Ileal resection

Competition or utilization

Fish tapeworm; Bacterial overgrowth; Increased demand

Vitamin inactivation

Nitrous oxide exposure

Slide 41 · Pernicious anemia is autoimmune malabsorption

A specific megaloblastic anemia associated with autoimmune atrophic gastritis.

Loss of gastric parietal cells reduces intrinsic factor production.

Defective ileal B₁₂ absorption eventually depletes stores and causes deficiency.

Core causal chain

Gastric autoimmune injury

Intrinsic factor deficiency

B₁₂ depletion

Slide 42 · Immune injury begins in the gastric mucosa

Autoreactive T-cell involvement in fundic mucosal injury.

Lymphocytes and plasma cells are prominent in the chronic gastritis.

Autoantibodies aid diagnosis but are not established as the sole cause of tissue injury.

Immune pathogenesis

T-cell mediated mucosal injury

Parietal cell atrophy

Intrinsic factor loss

Slide 43 · Antibodies in pernicious anemia

Antibody

Mechanism or diagnostic interpretation

Type I anti–intrinsic factor

Interferes with B₁₂ binding to intrinsic factor

Type II anti–intrinsic factor

Interferes with IF–B₁₂ complex binding to cubilin

Anti–parietal cell / proton pump

Frequently detectable; Lacks high specificity

Slide 44 · Autoimmune gastritis has characteristic morphology

Parietal and chief cells are lost from oxyntic mucosa of the body and fundus.

The mucosa becomes atrophic with lymphoplasmacytic inflammation.

Intestinal metaplasia can replace glandular epithelium with goblet-cell containing glands.

Morphologic sequence

Fundic gland injury

Oxyntic atrophy

Intestinal metaplasia

Slide 45 · The autoimmune context is clinically relevant

Pernicious anemia is associated with other autoimmune diseases.

Autoimmune thyroiditis and adrenalitis among associated conditions.

Its slow progression reflects depletion of long-standing B₁₂ stores after gastric injury.

Slide 46 · Nonautoimmune absorption defects

Etiology

Disrupted step

Gastrectomy

Loss of intrinsic factor–producing gastric mucosa

Achlorhydria / low pepsin

Inefficient release of food-bound B₁₂

Exocrine pancreatic disease

Inadequate haptocorrin breakdown

Ileal resection / ileitis

Failure of receptor-mediated B₁₂ uptake

Slide 47 · Other routes to functional deficiency

Intestinal organisms can compete for available vitamin B₁₂.

Increased physiologic demand may create relative deficiency in selected settings.

Nitrous oxide can oxidize and inactivate B₁₂, leading to symptomatic deficiency.

Slide 48 · Humans have two known B₁₂-dependent reactions

Two major cofactor-dependent enzymatic systems.

Methionine synthase

Methylmalonyl-CoA mutase

These reactions connect B₁₂ with one-carbon metabolism and methylmalonate handling.

Slide 49 · Methionine synthase: The one-carbon reaction

Methylcobalamin supports transfer of a methyl group from N⁵-methyl-THF.

Homocysteine

Methionine synthase + B₁₂

Methionine

The reaction also regenerates tetrahydrofolate (THF) from N⁵-methyl-THF.

Slide 50 · B₁₂ deficiency traps folate in a methylated form

The folate trap contributes to impaired thymidylate availability.

↓ Methionine synthase flux

↓ Available THF

↓ dTMP synthesis

Impaired DNA synthesis

THF = tetrahydrofolate; DTMP = deoxythymidine monophosphate.

Slide 51 · Defective DNA synthesis produces megaloblastosis

Nuclear maturation and division are delayed in proliferating marrow cells.

Cytoplasmic maturation and hemoglobin accumulation continue.

Nuclear–cytoplasmic asynchrony produces megaloblastic morphology.

Pathology linkage

Folate trap

Impaired DNA synthesis

Megaloblastic precursors

Slide 52 · Methylmalonyl-CoA mutase: The second reaction

Adenosylcobalamin is required in this pathway.

Methylmalonyl-CoA

B₁₂-dependent mutase

Succinyl-CoA

B₁₂ deficiency increases methylmalonic acid in plasma and urine.

Slide 53 · A proposed neurologic mechanism remains uncertain

Methylmalonate and propionate accumulation has been proposed to alter neuronal lipid metabolism.

Abnormal fatty-acid incorporation could destabilize myelin.

Hereditary mutase deficiency does not consistently reproduce SCD.

Scientific interpretation

Biochemical association: Established

Causal role in myelin breakdown: Proposed

Complete explanation: Unresolved

Slide 54 · Established findings versus mechanistic hypotheses

Established

Proposed / uncertain

B₁₂ deficiency causes SCD

Exact downstream biochemical lesion

Vacuolar myelin injury and axonal degeneration

Contribution of abnormal neuronal fatty acids

Elevated methylmalonate in deficiency

Methylmalonate as sufficient explanation for SCD

Slide 55 · The blood smear in megaloblastic anemia

Feature

Characteristic observation

Erythrocytes

Macro-ovalocytes; Size/shape variation

Neutrophils

Hypersegmented nuclei

Reticulocytes

Reduced count before effective treatment

Broader counts

Leukopenia or pancytopenia can develop

Slide 56 · Bone marrow: Megaloblastic dyspoiesis

Marrow is often hypercellular despite ineffective hematopoiesis.

Erythroid cells are enlarged, with immature nuclear chromatin.

Granulocytic precursors may include giant metamyelocytes; Megakaryocytes can be enlarged.

Cause of cytopenias

Disordered DNA synthesis

Intramedullary apoptosis

Ineffective hematopoiesis

Slide 57 · Folate deficiency is an important contrast

Both folate and B₁₂ deficiency can cause morphologically similar megaloblastic anemia.

Folate deficiency increases homocysteine but not methylmalonate in the source comparison.

The neurologic syndrome of SCD is associated with B₁₂, not uncomplicated folate deficiency.

Slide 58 · Biochemical and neurologic distinction

Feature

B₁₂ deficiency

Folate deficiency

Megaloblastic anemia

Yes

Yes

Homocysteine

Increased

Increased

Methylmalonate

Increased

Normal in source comparison

SCD neurologic findings

May occur

Not characteristic

Slide 59 · Diagnostic pattern

Serum B₁₂ is reduced in the classic deficiency pattern.

Homocysteine and methylmalonic acid may be elevated.

CBC can show macrocytic megaloblastic anemia with hypersegmented granulocytes.

Anti–intrinsic factor antibodies support a diagnosis of pernicious anemia.

Slide 60 · Intrinsic factor antibodies and etiologic diagnosis

Serum antibodies to intrinsic factor are highly specific for pernicious anemia.

Parietal cell antibodies are frequent but not individually specific.

An autoimmune etiology is distinct from other mechanisms of B₁₂ malabsorption.

Diagnostic question

B₁₂ deficiency present?

Autoimmune intrinsic-factor loss?

Other absorption defect?

Slide 61 · Atrophic glossitis reflects a systemic epithelial effect

A shiny, smooth, beefy-red tongue can occur in advanced deficiency.

Rapidly dividing epithelium shares vulnerability to impaired DNA synthesis.

Gastrointestinal and marrow manifestations provide context for neurologic disease.

Parallel tissue effects

Marrow: Megaloblastosis

Mucosa: Epithelial changes

Cord: Myelin injury

Slide 62 · Autoimmune gastric pathology persists after replacement

Vitamin B₁₂ replacement reverses the deficiency state but does not repair the autoimmune gastric atrophy.

Metaplasia and the associated gastric carcinoma risk persist.

The primary gastric disease remains a separate long-term pathology concern.

Slide 63 · Therapeutic response: Blood versus nerves

The hematologic response can include brisk reticulocytosis after parenteral B₁₂ replacement.

Megaloblastic marrow and gastrointestinal changes are readily reversible.

Severe established neurologic injury may not recover despite vitamin replacement.

Differing reversibility

Marrow: Typically responsive

Neurologic: Dependent on disease stage

Gastric autoimmunity: Persists

Slide 64 · Folate replacement does not treat SCD

Folate may improve the hematologic manifestations of B₁₂ deficiency.

It does not correct the associated neurologic injury and may allow neurologic deterioration to continue.

The source emphasizes excluding B₁₂ deficiency before treating megaloblastic anemia with folate alone.

Slide 65 · Case: Progressive gait difficulty

An adult develops several weeks of bilaterally symmetric lower-limb tingling, followed by sensory ataxia and increasing spastic weakness. Laboratory evaluation demonstrates vitamin B₁₂ deficiency.

Interpretation prompts

What combined spinal cord syndrome does this suggest?

Which major tract regions and microscopic lesions are expected?

Slide 66 · Case reasoning: Localize the combined syndrome

The distribution and tempo are compatible with subacute combined degeneration.

Dorsal and lateral cord tracts are affected together.

Myelin swelling and vacuolation are characteristic; Axonal degeneration occurs later.

Replacement before fixed severe deficits offers the best opportunity for improvement.

Slide 67 · Case: Megaloblastosis with subtle neurologic signs

A patient with autoimmune fundic atrophy has macro-ovalocytes, hypersegmented neutrophils, and mild bilateral lower-limb paresthesias. Folate is being considered for the anemia.

Interpretation prompts

Which deficiency must be excluded?

Why is folate alone insufficient for the neurologic risk?

Slide 68 · Case reasoning: Avoid masking neurologic disease

Autoimmune gastric disease can remove intrinsic factor and cause B₁₂ malabsorption.

The hematologic phenotype does not measure the full burden of neurologic injury.

Folate can improve anemia without correcting SCD.

Biochemical testing and investigation of the etiology are central to interpretation.

Slide 69 · Integrated clinicopathologic map

Mechanism

Tissue pathology

Clinical / laboratory result

Poor uptake / vitamin inactivation

Systemic cobalamin depletion

Low vitamin B₁₂

Folate-cycle disruption

Megaloblastic hematopoiesis

Macro-ovalocytes; Cytopenias

B₁₂-dependent metabolite defect

Methylmalonate accumulation

Elevated methylmalonic acid

Unresolved myelin injury pathway

Dorsal/lateral tract vacuolation

Ataxia, paresthesias, spastic weakness

Slide 70 · Four principles to retain

SCD combines dorsal and lateral spinal tract degeneration.

Microscopy progresses from myelin swelling and vacuolation to axonal loss.

B₁₂ deficiency may cause neurologic injury without conspicuous anemia.

Prompt B₁₂ replacement can improve outcomes; Established paraplegia has poor recovery.

Slide 71 · Clinical–pathologic reasoning checklist

Identify a gradually progressive, bilateral lower-limb sensory–motor syndrome.

Localize sensory ataxia and spastic weakness to combined spinal tract dysfunction.

Consider B₁₂ deficiency even when megaloblastic anemia is not prominent.

Investigate dietary intake, gastric intrinsic-factor loss, ileal disease, or vitamin inactivation.

Interpret MMA, homocysteine and B₁₂ findings in the wider clinicopathologic context.